{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-060481","form_type":"8-K","ticker":"CGEM","cik":"0001789972","company_name":"Cullinan Therapeutics, Inc.","filed_at":"2024-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.129576+00:00","generated_at":"2026-06-01T23:25:12.968251+00:00","sec_items":["2.02","5.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Cullinan Q1 net loss $37.3M; cash $434.8M; plans CLN-978 autoimmune IND Q3 2024; Meek appointed director","bullets":["Cash, cash equivalents, investments $434.8M as of March 31, 2024; plus $280M April private placement extends cash runway into 2028.","Q1 net loss $37.3M vs $58.1M Q1 2023; R&D expenses $30.6M, G&A $12.3M.","CLN-978 development pivoted to autoimmune diseases; IND for SLE expected Q3 2024; B-NHL study discontinued.","David Meek appointed to board effective May 15; Thomas Ebeling to resign June 26.","Initial CLN-619 combination & monotherapy data to be presented at ASCO June 1, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-060481","json":"https://secwatch.observer/filing/0000950170-24-060481.json","markdown":"https://secwatch.observer/filing/0000950170-24-060481.md","text":"https://secwatch.observer/filing/0000950170-24-060481.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1789972/000095017024060481/0000950170-24-060481-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1789972/000095017024060481/cgem-20240509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T23:25:12.968251+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d73ef739f3bde787b5fae8510d8ec33a6e63a83b","claim":"Cullinan Therapeutics, Inc. reported the first quarter ended March 31, 2024 results: net income Net loss (before items attributable to noncontrolling interest) for the first quarter of 2024 was $37.3 million.","evidence_excerpt":"Cullinan Therapeutics, Inc. (the \"Company\") announced its financial results for the quarter ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1789972/000095017024060481/0000950170-24-060481-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2024"},{"label":"Net income","value":"Net loss (before items attributable to noncontrolling interest) for the first quarter of 2024 was $37.3 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"31b771d8b1","claim":"David Meek was appointed as Class I Director at Cullinan Therapeutics, Inc..","evidence_excerpt":"the Board of Directors (the “Board”) of the Company appointed David Meek as a Class I director, effective May 15, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1789972/000095017024060481/0000950170-24-060481-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class I Director"}],"fact_type":"executive_change"},{"claim_id":"bd5fb882af","claim":"Thomas Ebeling resigned as Director at Cullinan Therapeutics, Inc..","evidence_excerpt":"Thomas Ebeling notified the Board of his intention to serve out his current term and resign as a director effective as of June 26, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1789972/000095017024060481/0000950170-24-060481-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}